

# Programme Agenda

## **Introduction**

Prof Martin Cowie

## **A review of recent SGLT2 inhibitor data**

Prof Giuseppe Rosano

## **Example patient case: New HFrEF – When and how should we initiate an SGLT2 inhibitor?**

Dr Javed Butler

## **Existing HFrEF: Augmenting existing SOC**

Dr Shelley Zieroth

## **How will SGLT2 inhibition provide the greatest impact in HFrEF?**

Prof Martin Cowie, Dr Javed Butler, Dr Shelley Zieroth

## **Summary**

Prof Martin Cowie

## Learning Objectives

- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases